Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2021 · 10-Q
Revenue$101.66M$101.66M+18.5% vs Q2 2020 Net Income$7.77M$7.77MN/M vs Q2 2020 EPS Diluted$0.16$0.16— vs Q2 2020 Gross Profit$47,376,000+42.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$32,159,000+6.9% Free Cash Flowderived$26,418,000+37.6% Margins · derivedGross margin46.6%+7.9 pt vs Q2 2020
Operating margin10.4%+13.8 pt vs Q2 2020
Net margin7.6%+7.9 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end